|
| Index | - | P/E | - | EPS (ttm) | -3.00 | Insider Own | 1.20% | Shs Outstand | 10.86M | Perf Week | -46.31% |
| Market Cap | 41.72M | Forward P/E | - | EPS next Y | - | Insider Trans | 4.39% | Shs Float | 0.18M | Perf Month | -53.75% |
| Income | -32.00M | PEG | - | EPS next Q | - | Inst Own | 22.60% | Short Float / Ratio | 14.87% / 0.96 | Perf Quarter | -75.28% |
| Sales | 4.80M | P/S | 8.69 | EPS this Y | 82.20% | Inst Trans | -9.66% | Short Interest | 0.03M | Perf Half Y | -71.69% |
| Book/sh | 0.50 | P/B | 6.02 | EPS next Y | - | ROA | -107.10% | Target Price | - | Perf Year | -58.29% |
| Cash/sh | 0.61 | P/C | 4.97 | EPS next 5Y | - | ROE | -263.30% | 52W Range | 2.94 - 17.43 | Perf YTD | -48.50% |
| Dividend | - | P/FCF | - | EPS past 5Y | 37.80% | ROI | -102.20% | 52W High | -81.24% | Beta | 0.06 |
| Dividend % | - | Quick Ratio | 2.20 | Sales past 5Y | -0.80% | Gross Margin | - | 52W Low | 11.19% | ATR | 0.71 |
| Employees | 40 | Current Ratio | 2.20 | Sales Q/Q | -12.50% | Oper. Margin | - | RSI (14) | 24.01 | Volatility | 24.93% 12.42% |
| Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | 67.90% | Profit Margin | - | Rel Volume | 0.56 | Prev Close | 3.01 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 27.74K | Price | 3.27 |
| Recom | 2.00 | SMA20 | -44.56% | SMA50 | -49.42% | SMA200 | -67.77% | Volume | 1,900 | Change | 8.64% |
 | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington. | |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite